Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21408924 | 0.89 | CA12 (0.38) | PTGDR2MEN1KMT2AKDM4ENOD1 | |
| SCHEMBL16546217 | 0.86 | ALDH1A1 (0.45) | PTGS2PTGS1PTGDR2LMNAMEN1 | |
| SCHEMBL16546232 | 0.81 | MEN1 (0.39) | PTGS2PTGS1LMNAMEN1KMT2A | |
| SCHEMBL15408335 | 0.81 | LMNA (0.41) | PTGS2PTGDR2LMNAMEN1KMT2A | |
| SCHEMBL16546201 | 0.81 | PIM1 (0.46) | PTGS2LMNAMEN1KMT2ARAB9A | |
| SCHEMBL30726626 | 0.81 | KIT (0.41) | PTGDR2LMNARAB9AGBA1NPC1 | |
| SCHEMBL15586641 | 0.80 | KIT (0.40) | — | |
| SCHEMBL16546198 | 0.80 | MAPT (0.36) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL16546238 | 0.80 | USP5 (0.34) | LMNARAB9AGBA1ALDH1A1MAPT | |
| SCHEMBL15586787 | 0.80 | MAOA (0.39) | PTGS2PTGDR2LMNAKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838898-B1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-01-18 | — | — | EP | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | IMPETIS BIOSCIENCES LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | IMPETIS BIOSCIENCES LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | IMPETIS BIOSCIENCES LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| EP-2838898-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013157021-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013157022-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013157022-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | BTK, MALT1, LCK | PTGS2 1161/4885PTGS1 336/4885PTGDR2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.